Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label ...

The FDA has updated the labeling for Kisunla™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer disease.

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...

The FDA approved a label update with a new titration schedule for donanemab (Kisunla), an anti-amyloid drug approved to treat ...

They slow progression of the disease, but they can have serious side-effects. – What are the medicines? Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope.

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The medicines are the first to slow the disease, which may give people extra ...

Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...

THE NHS is failing to keep up with science, experts blasted after breakthrough new dementia drugs were rejected again by the regulator. Charities and scientists said patients are being left behind … ...

Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid ...

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS The benefits from donanemab (also called Kisunla and made by Eli Lilly) and ...

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...